Progast

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Progast

Property Description
Active Ingredient Lansoprazole
Form Delayed-release oral capsules (Gastro-resistant)
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Reduction of gastric acid secretion
Origin Synthetic compound

Progast is a pharmaceutical preparation that contains the active ingredient Lansoprazole, positioning it as a medicine used primarily to manage conditions characterized by excessive acid production. As a Proton Pump Inhibitor (PPI), its potent and sustained action in reducing stomach acidity is clinically recognized. This classification reflects its efficacy compared to less specific acid reducers. Progast is typically available as a prescription-only medicine (Rx), underscoring its intended use for diagnosed gastrointestinal issues.

The Core Identity: What Type of Medicine is Progast?

Progast is an antiulcer agent containing the single active ingredient, Lansoprazole, meaning it is a monotherapy. Lansoprazole is a synthetic organic compound derived from the class of substituted benzimidazoles. This medication is universally classified under the Proton Pump Inhibitor group, which is structurally engineered to interact directly with the acid-secreting cells. The identity of Progast emphasizes its specific role in treating acid-related issues in adults and, where approved, pediatric patients.

Form, Composition, and Delivery System

The medicine is typically provided as delayed-release oral capsules, a specific form essential for ensuring efficacy. This structure makes Progast a gastro-resistant preparation. Because the active ingredient is highly vulnerable to chemical degradation by the extreme acidity of the stomach, this specialized form ensures the integrity of the Lansoprazole. The enteric-coated granules inside the capsule prevent premature destruction, allowing the active substance to be properly absorbed only after passing through the stomach and reaching the small intestine. This delivery system is vital for achieving the required systemic concentration to target the proton pumps effectively.

General Purpose: How it Works and What it Generally Helps

The general purpose of Progast is to achieve a controlled and significant reduction in overall stomach acidity. This sustained suppression results from the medicine’s ability to selectively inhibit the final step in the acid production pathway. By effectively blocking the proton pump, the medication lessens the chemical irritation caused by gastric acid, providing relief from discomfort. A typical use scenario involves providing symptomatic relief for patients experiencing persistent discomfort caused by the return of stomach contents into the esophagus.

What side effects are possible with Progast?

Possible Side Effects and Safety Information

The safety profile of Progast, which contains the active ingredient Lansoprazole, is classified by regulatory authorities (such as the FDA and EMA) into categories based on the frequency and system-organ class of the effects observed in clinical data and postmarketing surveillance.

Common Adverse Reactions

The most frequently documented adverse reactions, generally reported in at least 1% of patients, primarily involve the gastrointestinal and nervous systems. These include headache, diarrhea, abdominal pain, nausea, and constipation.

Serious and Duration-Related Safety Warnings

The regulatory safety information highlights specific, less frequent but clinically significant adverse reactions, particularly when associated with long-term use (typically over one year).

  • Bone Fracture: An increased risk of fractures of the hip, wrist, or spine is documented with long-term, high-dose therapy.
  • Hypomagnesemia: Low serum magnesium levels have been reported with prolonged treatment, sometimes requiring monitoring.
  • Acute Interstitial Nephritis (AIN): This is a rare, acute kidney condition that can occur at any time during therapy.
  • Infections: The medication is associated with an increased risk of Clostridium difficile-associated diarrhea.

Specific Safety Constraints

Official labeling includes constraints regarding use in specific populations and conditions. Use of this medicine is not recommended in pediatric patients under one year of age due to nonclinical safety concerns. Additionally, a symptomatic response to Progast does not preclude the presence of gastric malignancy, meaning further diagnostic evaluation may be necessary. The medicine is also contraindicated in patients receiving concurrent treatment with rilpivirine-containing products.

Overdose and Emergency Response

Progast Overdose and When to Seek Help

In the event that Progast (Lansoprazole) is taken in excess of the prescribed amount, immediate action is required by regulatory standards. It is mandated to seek medical help or contact a Poison Control Center right away, even if there are no immediately observable symptoms. This instruction stems from the necessity for professional monitoring and structured assessment following any over-exposure.


Documented Presentation and Management

Regulatory information confirms that no specific antidote is known for a Lansoprazole overdose. Treatment is officially defined as symptomatic and supportive, aiming to manage any clinical manifestations that may occur. While specific acute symptoms are not consistently listed in official prescribing information, potential manifestations may resemble known adverse effects. In documented cases, high ingestions, such as 600 mg, have been reported without resulting in adverse effects or symptoms of overdose.


Procedural Requirements

For the purpose of overdose management, the patient must be carefully monitored, and any unabsorbed material should be removed from the gastrointestinal tract. Official documents confirm that Lansoprazole is not significantly eliminated by haemodialysis due to its extensive protein binding. The necessity to contact emergency services immediately underscores the regulatory requirement for professional, structured support in all suspected cases of over-exposure.

Therapeutic Uses of Progast

Therapeutic Indications and Benefits

Progast is a herbal formulation used to manage various functional gastrointestinal disorders. It is primarily utilized to alleviate symptoms associated with impaired digestion and irregularities in the digestive tract.

Main Uses

  • Functional Dyspepsia: This includes the treatment of recurring signs of indigestion, such as upper abdominal pain, bloating, and a premature feeling of fullness after eating.
  • Irritable Bowel Syndrome (IBS): It is used to address the symptomatic discomfort of IBS, helping to manage abdominal cramping and altered bowel habits.
  • Gastritis: The formulation may be used to soothe the lining of the stomach when it is inflamed, helping to reduce sensations of burning or discomfort.
  • General Digestive Support: It is often applied to manage non-specific symptoms like flatulence, nausea, and intestinal spasms.

Mechanism and Benefits

Progast works through a combination of herbal extracts that target different parts of the digestive process. The primary benefits of its use include:

  • Motility Regulation: It helps coordinate the rhythmic contractions of the stomach and intestines, which is essential for moving food through the digestive system efficiently.
  • Anti-inflammatory Action: The botanical components possess natural properties that help reduce irritation within the gastrointestinal mucosa.
  • Reduction of Gas: By facilitating better digestion and reducing fermentation in the gut, it helps decrease the accumulation of gas and the resulting pressure.
  • Visceral Sensitivity: It may help in lowering the sensitivity of the nerves in the gut, which can reduce the perception of pain and discomfort in patients with sensitive digestive systems.

Regulatory References

  1. U.S. Food and Drug Administration (FDA)

Eligibility and Restrictions for Use

Progast (Lansoprazole) eligibility is strictly defined by regulatory documentation, detailing which populations are approved to use the medicine and which are prohibited or restricted.

Contraindications

The medicine is contraindicated for patients with a known severe allergy or hypersensitivity to lansoprazole or its components. It is also prohibited for patients concurrently receiving rilpivirine-containing products.

Age-Based Eligibility

Use is established for adults and pediatric patients aged 1 to 17 years for approved indications. However, use is not recommended for infants under one year of age for symptomatic GERD, as efficacy has not been demonstrated in that population.

Restrictions by Condition and Status

Patients with moderate or severe hepatic (liver) impairment require special caution and supervision, and a dose reduction may be necessary. In contrast, no dose adjustment is necessary for impaired renal function.

For reproductive status, use is not recommended during pregnancy unless clearly needed. Similarly, the medicine is not recommended for nursing mothers, requiring a decision to discontinue either the drug or breastfeeding. Adult patients should note that symptom relief does not preclude the presence of gastric malignancy, which is an eligibility-related restriction requiring diagnostic consideration.

What should I know about interactions with other medicines?

Progast (Lansoprazole) interacts with other products primarily through two documented mechanisms: altering gastric acidity and affecting the hepatic enzyme system. These interaction patterns are formally stated in regulatory documentation.

Official Interaction Restrictions

Co-administration with Rilpivirine-containing products is formally contraindicated by regulatory agencies. This prohibition is due to the potential for Progast to substantially decrease the plasma concentration of Rilpivirine by raising stomach pH.

Interaction Type Affected Substance Examples Regulatory Outcome
pH-Dependent Atazanavir, Erlotinib, Dasatinib, Digoxin Decreased exposure (most) or Increased exposure (Digoxin)
CYP-Mediated Warfarin, Tacrolimus, Methotrexate Increased plasma concentrations; requires monitoring

Co-administration with Sucralfate requires administration to be separated by at least mathbf30 minutes, as sucralfate significantly reduces Progast absorption. For interactions involving metabolic pathways, Progast may elevate and prolong serum levels of Methotrexate; temporary withdrawal of Progast should be considered during high-dose methotrexate therapy. Furthermore, co-administration with Food is officially documented to reduce the systemic exposure of Progast by up to 70 percent.

Mechanism of Action

Progast's action is defined by a targeted modulation of the intestinal epithelial and submucosal systems using Butyrate and L-Glutamine. Its mechanism of action can be understood through two primary domains:


Epithelial Barrier Fortification

This mechanism centers on providing the epithelial cells (colonocytes and enterocytes) with essential metabolic fuel (Butyrate and L-Glutamine) to supply metabolic precursors for cellular energy generation and proliferation. This metabolic input facilitates the remodeling and synthesis of the tight junction proteins that form the critical seal between the cells . The resulting physiological effect is a reduction in intestinal permeability, contributing to the selectivity of paracellular transport.


Local Immunomodulation and Signaling

This domain involves Butyrate acting as a key signaling molecule by binding to specialized receptors (GPCRs) on mucosal cells and immune cells. This interaction initiates a molecular cascade that modulates inflammatory signaling pathways, specifically inhibiting the production of pro-inflammatory cellular messengers within the gut wall. The key physiological consequence is the reduction in pro-inflammatory mediator production, affecting the activity level of local immune cells in the intestinal lining.

Dosage and Administration Information

How to Use Progast — Administration Guidelines

Progast (Lansoprazole) is administered according to standardized regimens. The guidelines emphasize the oral route of administration and specific timing to ensure the medication's intended function as a proton pump inhibitor is achieved.


Administration Scope

Instruction Detail
Route of Administration Oral (by mouth).
Dosing Schedule Standard doses are typically 15 mg or 30 mg once daily. For conditions involving pathological acid overproduction, the maximum daily dose can be up to 180 mg, administered in divided doses.
Timing in Relation to Meals The capsule is generally taken before eating, preferably in the morning.
Preparation Requirements The delayed-release capsule must not be crushed, chewed, or cut. It should be swallowed whole. If swallowing is difficult, the contents (granules) may be mixed with a small amount of specific soft food (e.g., applesauce) or acidic juice and swallowed immediately.
Age-Group Rules Older Adults typically do not require dose adjustment. Dose reduction should be considered in cases of severe hepatic impairment. Pediatric dosing is based on body weight and age.
Missed-Dose Rules If a dose is missed, take it as soon as remembered; if it is near the time for the next scheduled dose, the missed dose should be skipped.

Procedural Structure

The medication is designed for a once-daily frequency in most regimens, establishing a reliable dosing pattern. The requirement that the gastro-resistant capsule remain intact is a fundamental administration rule that supports the systemic absorption of Lansoprazole after passing through the stomach. This structured use protocol defines both short-term courses (e.g., 4 to 8 weeks) and long-term maintenance applications.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Progast (Lansoprazole)

The available research for Progast (Lansoprazole) includes Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses for conditions where researchers examined the role of acid reduction. These studies help show what has been observed so far in regulated environments, focusing on how symptoms were reported and measured in specific patient groups over defined time intervals.

Evidence for Use in Symptomatic GERD and Healing Erosions

Research into symptomatic Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE) has mainly used short-term RCTs. For symptomatic GERD, research examined patient-reported outcomes describing perceived discomfort, such as the measurement of heartburn and acid regurgitation frequency. For Erosive Esophagitis, studies monitored the endoscopic measurements of lesion resolution using criteria like endoscopic healing rates at set check-up times. The evidence contributes to the broader landscape by describing the observed lesion measurements over short periods, but these follow-up durations were limited.

Evidence for Use in Ulcer Treatment and H. pylori Eradication

Progast was studied for the treatment of active peptic ulcers, including those in the stomach (gastric) and the upper part of the small intestine (duodenal). Research explored outcomes related to physical discomfort, such as ulcer-associated pain, and monitored the endoscopic status of the physical lesion. The medicine was also evaluated in combination with antibiotics for the eradication of Helicobacter pylori infection, where studies focused on confirmed eradication rates and the association with duodenal ulcer recurrence. Research describes the measurements of eradication success, but these findings may vary geographically depending on regional antibiotic resistance patterns.

Studies in Special Populations and Uncertainties

Progast was evaluated in studies focusing on specific age groups, including children and adolescents. Research also included studies examining adults with a history of ulcers who also use NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) over an extended period. Despite the established evidence base from controlled trials, long-term effects on outcomes related to systemic or functional imbalance are not fully established, particularly for continuous use extending beyond one year. Additionally, the sample sizes were small in some pediatric trials.

Key Studies & References

  1. 25 Years of Proton Pump Inhibitors: A Comprehensive Review (Discussing maintenance/recurrence data and special populations)

Frequently Asked Questions (FAQ)

Common questions about Progast (FAQ)


Q: Can Progast be used for general stomach discomfort or only for specific conditions?

Regulatory labeling indicates that prescription use of Progast is intended for specific, diagnosed conditions such as ulcers or severe acid reflux disease. The over-the-counter form is indicated for relief of frequent heartburn, generally defined as occurring two or more days per week.


Q: Does Progast help with symptoms besides the main condition it treats?

Official product information indicates that the medication is intended for healing diagnosed conditions while also providing symptom relief. For example, it is indicated for the healing and the symptomatic relief associated with duodenal ulcers and severe acid reflux.


Q: Is it common to feel tired after starting Progast?

Tiredness, or fatigue, is listed in regulatory documentation as a common adverse reaction. This means it is reported to occur in a noticeable percentage of patients who take the medication.


Q: Is there a risk of dependency or withdrawal from Progast?

While Progast is not officially categorized as having dependency risk, abruptly stopping its use may cause a temporary increase in stomach acid production. This effect, known as rebound acid hypersecretion, may cause symptoms to return suddenly.


Q: Is it safe to stop taking Progast suddenly?

Abruptly stopping this medication may lead to temporary symptoms due to rebound acid hypersecretion. Because of this, healthcare providers often advise that discontinuation be managed by a gradual reduction to help minimize these effects.


Q: Does Progast interact with common vitamins or supplements?

Regulatory information states that long-term use may make it harder for the body to absorb Vitamin B12. Official labeling states that patients should inform their healthcare providers about all vitamins and supplements being used.


Q: Is it safe to consume alcohol while taking Progast?

Regulatory studies have indicated that consumption with high concentrations of alcohol may compromise the integrity of the capsule's special coating. This loss of integrity could potentially reduce the drug's intended effectiveness.


Q: What types of food should be avoided when taking Progast?

According to official product information, the medication should generally be taken before eating. Official regulatory documents state that taking the medication with food generally reduces its absorption into the system.


Q: Can I take Progast with common pain relievers like ibuprofen or acetaminophen?

Official drug interaction studies have not identified a direct pharmacological interaction between Progast and common over-the-counter pain relievers like ibuprofen or acetaminophen.


Q: Does Progast affect the effectiveness of birth control pills?

Clinical studies reviewed by regulatory agencies indicate that this medication does not significantly affect the bioavailability of common low-dose oral contraceptive pills. This suggests the drug does not reduce the overall effectiveness of birth control taken by mouth.


Q: How quickly does Progast start to work after the first dose?

Regulatory information suggests the chemical action of acid reduction may begin within one to two hours after the first dose. However, official regulatory information indicates it may take one to four days for a patient to feel the full symptomatic benefit.


Q: If Progast is working, how will I know?

Official information states that the success of the medication is measured by clinical outcomes, which for a patient means the symptom relief experienced (e.g., reduced heartburn). For erosive conditions, effectiveness is also measured by the healing observed during follow-up.


Q: Is Progast affected by weight or body mass index?

Official regulatory guidelines state that dosing for pediatric patients is explicitly determined by their weight. In contrast, standard adult dosing is generally standardized for specific indications.


Q: Is Progast a new drug or has it been used for many years?

Progast (Lansoprazole) is not a new drug; official records confirm its initial approval in the U.S. was in 1995. This means the medication has been extensively used and studied for many years.


Q: Why are there different dosages available for Progast?

Official regulatory documents list different medication strengths because specific strengths are indicated for different conditions. For instance, a higher strength may be used for healing severe conditions, while a lower strength may be used for long-term maintenance.


Q: What is the difference between brand name Progast and its generic form?

Regulatory agencies classify the generic form of the drug as bioequivalent to the brand name product. Regulatory classification means the generic contains the same active ingredient and is expected to achieve the same clinical benefit.


Q: Can Progast affect mood or cause anxiety?

Mood changes have been reported in official adverse event sections. Depression is listed as an uncommon side effect, and anxiety is reported with an unknown incidence.


Q: Does Progast change the color or frequency of bathroom habits?

Changes in bathroom frequency are commonly reported, including diarrhea and constipation. While rare, the occurrence of bloody, black, or clay-colored stools is listed as a serious adverse event.


Q: Can Progast be taken with antacids like Tums?

Official drug interaction information confirms that antacids can be taken with this medication if needed.


Q: Is there a maximum time someone can be on Progast?

Most short-term treatments are generally limited to 4 to 12 weeks for indications like ulcer or esophagitis healing. Treatment for certain chronic conditions may continue for longer, but official labeling discusses the long-term safety considerations associated with prolonged use.


Q: What is the non-medical term for the condition Progast treats?

The non-medical term commonly used in official information to describe the primary symptoms that Progast helps to treat is heartburn or acid reflux.


Q: What does the drug's packaging say about driving or operating machinery?

Regulatory documents indicate that caution may be necessary when driving or operating machinery. This is because side effects like dizziness, vertigo, and visual disturbances have been reported.


Q: How long does Progast stay in your system after the last dose?

The physical half-life of the drug in the bloodstream is quite short, typically about 1.5 hours. However, the clinical effect of acid reduction lasts much longer (over 24 hours) because the drug permanently binds to the acid-producing cells.

How should Progast be stored and disposed of?

Official Storage Requirements

Progast (Lansoprazole delayed-release capsules) requires strict adherence to regulatory storage standards to maintain the integrity of its specialized formulation. The medication must be stored at controlled room temperature—typically defined as 20 C to 25 C (68 F to 77 F).

Crucially, the product must be protected from moisture and must not be refrigerated, as both conditions can compromise the capsule's gastro-resistant coating. The medicine must be kept in its original container and, if supplied in a bottle, the cap must be tightly closed.

Mandatory Disposal Instructions

For safety, it is an official requirement to keep this and all medicines out of the sight and reach of children.

When disposing of unused or expired Progast, do not dispose of it via household trash or wastewater (such as flushing down the toilet). Instead, unused portions must be returned to a pharmacist or a local drug take-back program for proper environmental handling, as documented in regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Progast found in:

A-Z Index: